MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ
47.41
-1.49
-3.05%
After Hours: 47.25 -0.16 -0.34% 19:48 08/28 EDT
OPEN
48.82
PREV CLOSE
48.90
HIGH
48.82
LOW
47.25
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
55.67
52 WEEK LOW
25.17
MARKET CAP
7.95B
P/E (TTM)
123.17
1D
5D
1M
3M
1Y
5Y
1D
THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)
Seeking Alpha · 1d ago
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
NASDAQ · 1d ago
Trump Trade: U.S. considering new semiconductor tariffs
TipRanks · 2d ago
Did Positive Vibrance-1 Data and Brilliance Phase 3 Launch Just Shift Alkermes' (ALKS) Investment Narrative?
Simply Wall St · 2d ago
Alkermes’ alixorexton featured in published Phase 2 study of narcolepsy
TipRanks · 4d ago
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Barchart · 4d ago
Weekly Report: what happened at ALKS last week (0817-0821)?
Weekly Report · 5d ago
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
NASDAQ · 08/21 16:40
More
About ALKS
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.

Webull offers Alkermes Plc stock information, including NASDAQ: ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.